Showing 4511-4520 of 10192 results for "".
- Soliton's RAP Technology Now Cleared for Cellulitehttps://practicaldermatology.com/news/solitons-rap-technology-now-cleared-for-cellulite/2460681/The FDA has cleared Soliton Inc.’s Rapid Acoustic Pulse (RAP) technology for the short-term improvement in the appearance of cellulite. Harnessing the power of sound, the unique, rapid-pulsed technology safely and comfortably breaks apart the fibrous septa bands beneath the skin that cause
- Bristol Myers Squibb: Positive Topline Results Pivotal Phase 3 Psoriasis Study of Deucravacitinibhttps://practicaldermatology.com/news/bristol-myers-squibb-positive-topline-results-pivotal-phase-3-psoriasis-study-of-deucravacitinib/2460678/Bristol Myers Squibb shared positive results from POETYK PSO-2, the second pivotal Phase 3 trial evaluating deucravacitinib, a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to s
- NRS Survey Finds Rosacea Patients Lack Knowledge of Antibiotic Resistancehttps://practicaldermatology.com/news/nrs-survey-finds-rosacea-patients-lack-knowledge-of-antibiotic-resistance/2460671/A majority of rosacea patients have never heard of antibiotic resistance, results of a recent survey by the National Rosacea Society (NRS) show. Yet topical or oral antibiotics are among the most commonly prescribed treatments for rosacea. The NRS’s rec
- Soliton, US Navy to Collaborate on Study of RAP for Fibrotic Scarshttps://practicaldermatology.com/news/soliton-us-navy-to-collaborate-on-study-of-rap-for-fibrotic-scars/2460670/Soliton, Inc. will collaborate with the US Navy to conduct a multi-treatment proof-of-concept clinical study to evaluate the safety and efficacy of multiple treatments with Soliton's Rapid Acoustic Pulse (RAP) device for the improvement in the appearance of fibrotic scars. The study
- Candela Launches Frax Pro Systemhttps://practicaldermatology.com/news/candela-launches-frax-pro-system/2460665/Candela’s Frax Pro system is now available. This platform features Frax 1550 and the novel Frax 1940 applicators. The Frax 1940 handpiece delivers a 1940 nm wavelength laser beam for a shallow, epidermal approach, with focal reach extending to approximately 200 μm in
- Arcutis Starts Phase 3 Trials of Topical Roflumilast Cream for ADhttps://practicaldermatology.com/news/arcutis-starts-phase-3-trials-of-topical-roflumilast-cream-for-ad/2460654/Arcutis Biotherapeutics, Inc. is starting their pivotal Phase 3 clinical trials evaluating topical roflumilast cream (ARQ-151) as a potential treatment for atopic dermatitis (AD). Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and s
- Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://practicaldermatology.com/news/ajinomoto-bio-pharma-services-and-revance-therapeutics-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2460641/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.
- DermOQ Oxygen Lab Completes Purchase of ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://practicaldermatology.com/news/dermoq-oxygen-lab-completes-purchase-of-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2460640/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate custom
- Aerolase Introduces Skin of Color Forumhttps://practicaldermatology.com/news/aerolase-introduces-skin-of-color-forum/2460639/Aerolase Corp. is launching a Skin of Color Forum (SOCF). "This Forum is much needed and transformative. It's been rewarding to work alongside Aerolase to shape its leadership in advancing skin of color dermatology," sa
- For Upper Facial Lines, DaxibotulinumtoxinA Succeeds in Phase 2https://practicaldermatology.com/news/for-upper-facial-lines-daxibotulinumtoxina-succeeds-in-phase-2/2460637/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48